Rankings
▼
Calendar
ESPR Q1 2025 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
ESPR
Esperion Therapeutics, Inc.
$577M
Q1 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$65M
-52.8% YoY
Gross Profit
$33M
51.5% margin
Operating Income
-$22M
-34.0% margin
Net Income
-$40M
-62.2% margin
EPS (Diluted)
$-0.21
QoQ Revenue Growth
-6.0%
Cash Flow
Operating Cash Flow
-$23M
Free Cash Flow
-$23M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$324M
Total Liabilities
$750M
Stockholders' Equity
-$426M
Cash & Equivalents
$115M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$65M
$138M
-52.8%
Gross Profit
$33M
$128M
-73.8%
Operating Income
-$22M
$72M
-130.6%
Net Income
-$40M
$61M
-166.3%
Revenue Segments
Product
$35M
54%
Collaboration Revenue
$30M
46%
← Q4 2024
All Quarters
Q2 2025 →